Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Iofina LSE:IOF London Ordinary Share GB00B2QL5C79 ORD 1P
  Price Change % Change Share Price Shares Traded Last Trade
  +0.40p +3.11% 13.25p 109,654 16:35:28
Bid Price Offer Price High Price Low Price Open Price
13.00p 13.50p - - -
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
General Financial 20.83 -9.79 -7.60 16.9

Iofina (IOF) Latest News

More Iofina News
Iofina Takeover Rumours

Iofina (IOF) Share Charts

1 Year Iofina Chart

1 Year Iofina Chart

1 Month Iofina Chart

1 Month Iofina Chart

Intraday Iofina Chart

Intraday Iofina Chart

Iofina (IOF) Discussions and Chat

Iofina Forums and Chat

Date Time Title Posts
26/3/201918:28Iofina recovery4,464
14/2/201908:51IOF tipsters2,611
25/12/201812:23Iofina Private Investors Meeting - Cheltenham120
14/12/201808:29IOFINA ABOUT TO ROCKET ON TRADING UPDATE!18
02/6/201710:21Iofina41,441

Add a New Thread

Iofina (IOF) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
09:10:4213.9554,8277,648.37O
09:10:2313.8054,8277,566.13O
View all Iofina trades in real-time

Iofina (IOF) Top Chat Posts

DateSubject
26/3/2019
08:20
Iofina Daily Update: Iofina is listed in the General Financial sector of the London Stock Exchange with ticker IOF. The last closing price for Iofina was 12.85p.
Iofina has a 4 week average price of 12p and a 12 week average price of 11p.
The 1 year high share price is 24p while the 1 year low share price is currently 10p.
There are currently 127,569,398 shares in issue and the average daily traded volume is 217,937 shares. The market capitalisation of Iofina is £16,902,945.24.
19/3/2019
07:18
mesquida: The share price performance so far this year has been frustrating to put it mildly. Despite the bullish picture that is now emerging in terms of production figures, and iodine prices, we have not really had a good run. The restructuring of the debt, which ruled out future equity dilution, was a major positive which once again failed to get the share price moving into top gear. I would wager that most of us would have assumed that the extinguishing of potential dilution was just too much to hope for, but that is what we got, no wonder that Tom talked about potentially removing a lid on the stock price ! And yet that lid is still there. I can only assume that there is one big seller behind the scenes, one might think that it is Stena but surely they would be deemed to be insiders given that the debt restructuring has still not been officially signed off. Let us hope that yesterday's article on Proactive Investor puts the Company back into the spotlight and that any resultant new buyers can soon clear up the rest of what is left of the seller's holding. Perhaps then the seller might see fit to put out a holdings rns, a luxury which so far ( surprisingly ) we have not enjoyed !
27/2/2019
08:19
pjl4: Still looking for a free share price streaming after moniam now charges. Someone kindly suggested inv.com. Did sign up, then added portfolio but still couldn't find share price streaming. Then lots of ads began appearing on my computer!! Every day to my email. Will unsubscribe. Is there another free share price streaming please?
14/2/2019
06:41
luckyorange: Just looking back through some old posts and good to be reminded of what was and what is now! Thanks johnsdale. johnsdale - 13 Oct 2018 - 21:36:01 - 2948 of 3916 Iofina recovery - IOF I also spent sometime today going back over my notes and the AGM and other information I picked up by speaking to the company about the debt situation in June as the situation has been taken slightly out of context. Iâ€͐2;m going to spell it out in layman’s terms as I think there are a huge amount of lurkers here waiting for clarity on the debt and itâ€T82;s hard to piece the information together, my aim of late has to keep a constructive dialogue on the issue as itâ€T82;s the one single impediment to this share price hitting high 20â€T82;s low 30â€T82;s with the iodine price rises and record production figures we saw this week. Stena originally lent the company 15 million and Pancrea a further 5 million dollars over a 2 year period at an interest coupon of 6.5%. This debt was renegotiated to 6% interest and the deal at the time allowed for the debt to be converted into shares at 18p -25p and 32p respectively. The debt also allowed for a 10 million overdraft facility for expansion and the debt interest to be rolled up. Itâ€T82;s important to understand the relationship Iofina have with Stena and Pancrea in that they are both shareholders and know the company very well. When this deal was made the share price was 5p, had they wanted to take the company over at that stage they could have done so with little resistence by simply calling in the debt or placing the convertibles at the current share price allowing monumental amounts of dilution, but they elected not too. I only state this point as if they didn’t then and all Iofina’s Comments relate to them not wanting to run the plants why would they change there mind now. All the comments from the company In June indicate Stena want to gradually reduce there debt exposure here down by 50%. Information from the company was they are happy to keep the 18p convertables in play. Realistically this is why they were happy to sell above 18-20p but also why I didn’t believe (still donâ€482;t) that they were selling below this point. Also Banks (Pancrea) snapped up shares to the value of what Stena offloaded. Always hard to know what his motivation is here as he no longer comments, However again if there was a motivation to pull the debt in it makes zero sense for Banks raise his stake in Iofina as itâ€T82;s literally money he doesn’t have to spend. So far they have drawn down 3 million from the overdraft which produced IO7 and as the news shows this week an incredibly profitable plant. So the debt in focus is circa 18 million as Stenas full proportion, the comments remain this is a gradual reduction down to 50% but even assuming they want half back next June it would look as follows: They effectively would like 9 million back at this point if we remove the word gradual. Iofâ€482;s issue is they are so close to being in a position to clear the entire debt over a 2 year term, but they have to borrow more to do so, however vindicated by the price rises and record production figures this week. I could go into why I think itâ€T82;s actually financially easy to do and the comments around new debt being negotiated at 7% coupons, but that is more subjective and Iâ€͐2;ve tried to keep this post aligned with the facts as told to us by the company to date. Iâ€͐2;ve done this as Iâ€͐2;ve found this management team to be highly honest and reliable which combined with my own research is why Iâ€͐2;ve taken such a large position here. I originally invested at 60p and averaged down slightly but my breakeven remains around 13-14p mostly because I did simailar research prior to the last debt Deal and took a large position then. I think Hernando makes some great points as to why he feels this could have a negative outcome and Iâ€͐2;ve always said without opposing views a board is worthless, sorry for my long post and I hope people will correct any errors in the above, the aim is to spread knowledge and understanding, and show why myself and people like Squire believe this will comfortably get back to the 30â€T82;s and ideally low 40â€T82;s On a 1-2 year investment view. Enjoy what remains of your weekend
12/2/2019
12:13
bocker01: Andrew Darley | adarley@finncap.com IOF) : Corp Removing the shackles Key data •Share price (p) 17.7 •Target price (p) 34.0 •Market cap (£m) 22.6 •Enterprise value (£m) 40.5 Iofina has successfully restructured its convertible and term loan facilities, with convertibility removed and repayment pushed out a year to mid-2020. Iofina will incur a higher interest rate as a result and can no longer capitalise interest payments, although this still looks the best outcome that could have been expected and removes a major issue that has been weighing on the shares. In our forecasts we have delayed the assumed IOsorb™ plant expansions by 6-9 months, which reduces our EBITDA forecasts by 11-12%. This sees our DCF-based price target fall 3% to 34p. Nevertheless, Iofina still offers material upside and strong leverage to improving iodine prices and its continued operational recovery.
06/2/2019
14:24
goofy1: Company seems to have a lot of flexibility. 30 September 2016 Iofina plc ("Iofina", the "Group" or the "Company") (LSE AIM: IOF) Completion of US$20 million Convertible Secured Loan Notes Restructure and additional US$10 million Secured Facility Iofina, specialists in the exploration and production of iodine and iodine specialty chemical derivatives, is pleased to report the completion of the restructuring of convertible secured loan notes in the amounts of US$15 million to Stena Investment S.á.r.l. ("Stena") and US$5 million to Panacea Limited ("Panacea") (together, the "Notes" and the "Noteholders"). The general terms of this debt restructuring were first reported in June 2016, and the documentation between the parties has now been completed. Highlights: Restructuring of $20m Convertible Notes · Reissued as Convertible Secured Notes redeemable 1 June 2019 · Convertible in three equal tranches at 18p, 25p and 32p per share · Interest payable at 5% per annum or may be rolled-up and capitalised New $10m Secured Facility with Stena · Repayable on 1 June 2019 · Interest payable at 6% per annum · Funds to be used to support and develop the Group's iodine operations Cumulative effect of these agreements is to remove uncertainty surrounding the Group's balance sheet and funding position, and provide operational flexibility to develop the Group's iodine production and derivatives operations. Commenting on today's announcement, Dr. Thomas Becker, President & CEO of Iofina plc stated: "The Board is delighted to announce the completion of the documentation for the convertible debt restructuring and the additional debt facility, the terms of which were first announced in June. Iofina values the partnerships with Panacea and Stena and the Group now has additional resources to execute growth plans." Details of the agreements: On 29 September 2016 the Company executed two Convertible Secured Loan Note Instruments on the same terms and conditions, under which loan notes with a nominal value of US$1 each were issued to Stena in an aggregate principal amount of US$15,000,000 and to Panacea in an aggregate principal amount of US$5,000,000. These new loan Notes have refinanced and replaced in their entirety the previously issued loan notes in the same principal amounts as regards Stena and Panacea respectively. The principal terms and conditions attaching to the Notes are as follows: (a) unless previously converted into ordinary shares of £0.01 each in the capital of the Company ("Ordinary Shares") or redeemed, the Notes are redeemable at par together with capitalised, accrued and unpaid interest on 1 June 2019; (b) the Company is entitled to redeem any of the Notes at any time prior to 1 June 2019 without penalty; (c) any or all of the Notes outstanding may be converted into Ordinary Shares by the Noteholders at any time subject to prior written notice to the Company of 28 days or such shorter period as may be agreed by the Company; (d) the conversion rates to be used for the conversion of the Notes into Ordinary Shares are, as regards the total amount of the Notes outstanding, one third at 18p per share, one third at 25p per share, and one third at 32p per share; (e) the Company may require that any or all of the Notes outstanding be converted into Ordinary Shares following the publicly quoted closing price per Ordinary Share being 50p or more for at least five consecutive trading days; (f) interest is payable quarterly in arrears at the rate of 5% per annum. The Company may at its sole discretion elect to roll-up quarterly interest payments without limit, in which case the interest rolled-up will be capitalised and form part of the principal balance of the Notes; (g) the Noteholders may resolve to accept payment of any capitalised or accrued interest by the issuance of Ordinary Shares, using a conversion rate of 32p per share; (h) unless the prior consent of the Company has been obtained, the Noteholders are not entitled to sell or transfer the Notes except to certain related parties; and (i) no conversion shall be permitted in the event that, upon such conversion, it would have the effect of establishing or otherwise increasing a holding in Ordinary Shares of a Noteholder (whether by itself or in conjunction with the holdings of any "concert parties" (as defined in The City Code on Takeovers and Mergers (the "Code))) which could potentially trigger a mandatory offer having to be made for other Ordinary Shares under Rules 9 and 37 of the Code. A conversion may be so permitted if the Company and the relevant Noteholder agree to it in writing but subject at all times to the receipt of any prior written approval which may be required from The Panel on Takeovers and Mergers. The Notes are secured against the assets of the Group, by a share pledge and a debenture granted by the Company, and by further pledges, security agreement and guarantees granted by certain subsidiaries of the Company. On 29 September 2016 the Company entered into an agreement for a Term Loan Facility of up to US$10,000,000 (the "Facility") with Stena. The principal terms and conditions attaching to the Facility are as follows: (a) the Facility is to be utilised for capital expenditure and working capital purposes in connection with (i) the Company's iodine and iodine derivatives production, refinement, marketing and sales activities; (ii) water depot project; and (iii) iodine and natural gas operations, as carried out at the Company's sites in the United States of America; (b) the Company may draw down up to US$3,000,000 of the Facility on request and in tranches of not less than US$250,000 or such other amount as may be agreed; (c) drawdowns of amounts of the Facility in excess of US$3,000,000 are dependent upon completion of a detailed due diligence exercise and satisfaction with the results by Stena regarding the prevailing state of affairs relating to the Group and its assets; (d) interest is payable quarterly in arrears at the rate of 6% per annum. The Company may elect to capitalise the interest, in which case the interest will be rolled-up and treated as principal outstanding and repaid on 1 June 2019; (e) all amounts outstanding under the Facility are repayable in full on 1 June 2019; (f) the Company may repay any amounts outstanding under the Facility at any time without penalty. The Company may reborrow amounts previously repaid subject to the consent of Stena; (g) for so long as amounts are outstanding under the Facility the Company is not to make any payments to shareholders or other debt providers, including principal amounts outstanding under the Notes, without Stena's prior consent; and (h) without the prior consent of Stena, the Group is not to take on further borrowings, except for debt at an interest rate lower than the Facility rate that is used to repay amounts outstanding under the Facility. The Facility is secured against the assets of the Group under the same arrangements as set out above in relation to the Notes. Conversion premiums to current share price: The premiums over the closing price per Ordinary Share of 13.75p on 29 September 2016 represented by the conversion rates applicable to the Notes are as follows: · Stena o US$5 million at a conversion price of 18p, which represents a premium of 31% to the closing price of 13.75p on 29 September 2016; o US$5 million at a conversion price of 25p, which represents a 82% premium to the closing price of 13.75p on 29 September 2016; and o US$5 million plus any capitalised or accrued interest at a conversion price of 32p, which represents a 133% premium to the closing price of 13.75p on 29 September 2016 · Panacea o US$1.67 million at a conversion price of 18p, which represents a premium of 31% to the closing price of 13.75p on 29 September 2016; o US$1.67 million at a conversion price of 25p, which represents a 82% premium to the closing price of 13.75p on 29September 2016; and o US$1.67 million plus any capitalised or accrued interest at a conversion price of 32p, which represents a 133% premium to the closing price of 13.75p on 29 September 2016 Conversion shares percentage of enlarged share capital: Based on the par value of the Notes of US$20 million and the current GBP/USD exchange rate (and excluding any interest which may be converted) and assuming all Notes were converted, the Ordinary Shares to be issued on the conversion of the total principal amount of the Notes would represent approximately 65 million shares or approximately 34% of the then enlarged issued share capital of the Company.
13/10/2018
21:36
johnsdale: I also spent sometime today going back over my notes and the AGM and other information I picked up by speaking to the company about the debt situation in June as the situation has been taken slightly out of context. I’m going to spell it out in layman’s terms as I think there are a huge amount of lurkers here waiting for clarity on the debt and it’s hard to piece the information together, my aim of late has to keep a constructive dialogue on the issue as it’s the one single impediment to this share price hitting high 20’s low 30’s with the iodine price rises and record production figures we saw this week. Stena originally lent the company 15 million and Pancrea a further 5 million dollars over a 2 year period at an interest coupon of 6.5%. This debt was renegotiated to 6% interest and the deal at the time allowed for the debt to be converted into shares at 18p -25p and 32p respectively. The debt also allowed for a 10 million overdraft facility for expansion and the debt interest to be rolled up. It’s important to understand the relationship Iofina have with Stena and Pancrea in that they are both shareholders and know the company very well. When this deal was made the share price was 5p, had they wanted to take the company over at that stage they could have done so with little resistence by simply calling in the debt or placing the convertibles at the current share price allowing monumental amounts of dilution, but they elected not too. I only state this point as if they didn’t then and all Iofina’s Comments relate to them not wanting to run the plants why would they change there mind now. All the comments from the company In June indicate Stena want to gradually reduce there debt exposure here down by 50%. Information from the company was they are happy to keep the 18p convertables in play. Realistically this is why they were happy to sell above 18-20p but also why I didn’t believe (still don’t) that they were selling below this point. Also Banks (Pancrea) snapped up shares to the value of what Stena offloaded. Always hard to know what his motivation is here as he no longer comments, However again if there was a motivation to pull the debt in it makes zero sense for Banks raise his stake in Iofina as it’s literally money he doesn’t have to spend. So far they have drawn down 3 million from the overdraft which produced IO7 and as the news shows this week an incredibly profitable plant. So the debt in focus is circa 18 million as Stenas full proportion, the comments remain this is a gradual reduction down to 50% but even assuming they want half back next June it would look as follows: They effectively would like 9 million back at this point if we remove the word gradual. Iof’s issue is they are so close to being in a position to clear the entire debt over a 2 year term, but they have to borrow more to do so, however vindicated by the price rises and record production figures this week. I could go into why I think it’s actually financially easy to do and the comments around new debt being negotiated at 7% coupons, but that is more subjective and I’ve tried to keep this post aligned with the facts as told to us by the company to date. I’ve done this as I’ve found this management team to be highly honest and reliable which combined with my own research is why I’ve taken such a large position here. I originally invested at 60p and averaged down slightly but my breakeven remains around 13-14p mostly because I did simailar research prior to the last debt Deal and took a large position then. I think Hernando makes some great points as to why he feels this could have a negative outcome and I’ve always said without opposing views a board is worthless, sorry for my long post and I hope people will correct any errors in the above, the aim is to spread knowledge and understanding, and show why myself and people like Squire believe this will comfortably get back to the 30’s and ideally low 40’s On a 1-2 year investment view. Enjoy what remains of your weekend
05/11/2017
15:33
superg1: On the dilution side you have $20 mill at 25p per share average re the loan notes. Current exchange rate 1.3 it adds about 60 mill shares making it around 180 mill in issue. The debt not yet drawn down in full 6% interest pa. Notes payable by June 2019. I see IOF can demand conversion of the notes if the share price goes over 50p for 5 consecutive days. "e) the Company may require that any or all of the Notes outstanding be converted into Ordinary Shares following the publicly quoted closing price per Ordinary Share being 50p or more for at least five consecutive trading days;" Using a PE of 15 if they were in profit then it equates to .83p per mill profit. So £5 mill profit would mean around a 40p share price then add in the growth factor if that was in play. All things being equal then each $1 rise in the iodine price adds about 6p. That assumes io7 and 8 in play with around 800mt plus per year. In short if the iodine price does well then the IOF share price is going to take off.
06/6/2017
06:43
rogerbridge: We have to remember that there is an election in two days time and many have taken money off the table, since the Labour Party apperering to be neck and neck with the Conservatives. Some weeks ago, it looked a stroll for May, now investors are not sure. I think May will win, and there will be some re-investing, otherwise, the market is probably in for a drop. One thing is sure, as the iodine price increases, so will the IOF share price.
20/12/2016
08:29
jonnybig: Half a pence half a pence half a pence downward Into the valley of death Fell the IOF share price LOL!!! JonnyB:)
03/8/2016
10:35
rogerbridge: The oil price is down at the moment, interestingly, around February time a chartist who is usually quite accurate forecast that crude would be $46 in July, down to £38.43 in July and back up to $60 in November. Who knows, but traders can not make money unless the crude price goes up or down, there is no money to be made if the price is flat. The result is that we get volitility with all of the money slopping about in the markets, due to Q.E. Money has to go somewhere and eventually it will go back into crude, the question is when. It's a pity about the IOF share price but the board have never been ones to release rns's and talk things up.
Iofina share price data is direct from the London Stock Exchange
Your Recent History
LSE
IOF
Iofina
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20190326 20:27:51